Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06007508 · ClinicalTrials.gov registry record · Phase 2
Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis
A Phase 2 study, sponsored by HealthPartners Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT06007508 is a Phase 2 study that was terminated before completion, run by HealthPartners Institute. The registered enrollment target is 8 participants.
The verdict
NCT06007508, a Phase 2 study, was terminated before completion, sponsored by HealthPartners Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
Diabetic ketoacidosis (DKA) is a medical emergency that is associated with significant morbidity and mortality for both patients with type I and type II diabetes. By correcting hyperglycemia and inhibiting the release of free fatty acids, insulin administration leads to decreased ketone formation and resolution of acidosis. Short-acting intravenous insulin is often preferred to subcutaneous administration for initial management due to its short half-life and ease of titration, but patients will eventually need to transition to subcutaneous insulin prior to discharge. The timing of initiation or resumption of home long-acting subcutaneous insulin is controversial in the treatment of DKA. It is currently unknown if resuming a portion or all of the patient's home basal regimen during the initial treatment phase of DKA will provide an impact on patient care. The purpose of this study is to evaluate the impact of early glargine administration if the patient was not previously on basal insulin or resuming the patient's home basal insulin regimen within two hours after the start of the intravenous insulin infusion in addition to usual care will improve patient outcomes.
Interventions
- DRUG Insulin Glargine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-05-31 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06007508
The ClinicalTrials.gov registry entry for NCT06007508 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HealthPartners Institute, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Insulin Glargine is the first listed.
NCT06007508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06007508 about?
NCT06007508 is a clinical study titled "Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis". Diabetic ketoacidosis (DKA) is a medical emergency that is associated with significant morbidity and mortality for both patients with type I and type II diabetes. By correcting hyperglycemia and inhibiting the release of free fatty acids, insulin administration leads to decreased ketone formation an...
What is the current status of trial NCT06007508?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2022-05-31. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT06007508?
The interventions under investigation include: Insulin Glargine (DRUG).
Who is sponsoring clinical trial NCT06007508?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.